Payment overview · 2025
General Payments
$785.13
43 reported records · 8 companies
Healthcare provider profile · identity verified
Raza Ashraf, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BINGHAMTON, NY · NPI 1508249459
Verified facts
What the public records show
CMS Open Payments records show Raza Ashraf, D.O. received $785.13 in general payments during 2025 across 43 reported records.
ABBVIE INC. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $297.81 | 37.9% | 15 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $120.36 | 15.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $102.87 | 13.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $98.01 | 12.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.55 | 7.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.61 | 6.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.21 | 5.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.71 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $785.13 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $245.28 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.27 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $60.19 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.17 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $54.30 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.53 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.53 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.61 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.61 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.57 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.57 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.21 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.73 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 106 |
| Omeprazole | Omeprazole | 324 | 102 |
| Lisinopril | Lisinopril | 303 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 94 |
| Simvastatin | Simvastatin | 202 | 59 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 176 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 59 |
| Losartan Potassium | Losartan Potassium | 160 | 54 |
| Metformin Hcl | Metformin Hcl | 154 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 50 |
| Gabapentin | Gabapentin | 146 | 39 |
| Ozempic | Semaglutide | 136 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 64 |
| Sertraline Hcl | Sertraline Hcl | 104 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 30 |
| Montelukast Sodium | Montelukast Sodium | 84 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 32 |
| Famotidine | Famotidine | 75 | 45 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 29 |
| Jardiance | Empagliflozin | 68 | 19 |
| Furosemide | Furosemide | 65 | 18 |
| Potassium Chloride | Potassium Chloride | 63 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 21 |
| Valacyclovir | Valacyclovir Hcl | 60 | 14 |
| Eliquis | Apixaban | 59 | 18 |
| Glipizide Er | Glipizide | 58 | 16 |
| Bupropion Xl | Bupropion Hcl | 57 | 19 |
| Carvedilol | Carvedilol | 55 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 21 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | 16 |
| Valsartan | Valsartan | 52 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 24 |
| Metformin Hcl Er | Metformin Hcl | 49 | 13 |
| Methylprednisolone | Methylprednisolone | 49 | 48 |
| Trulicity | Dulaglutide | 49 | 15 |
| Alendronate Sodium | Alendronate Sodium | 47 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 18 |
| Lorazepam | Lorazepam | 47 | 15 |
| Ketoconazole | Ketoconazole | 44 | 21 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Baclofen | Baclofen | 39 | 17 |
| Meloxicam | Meloxicam | 39 | 19 |
| Alprazolam | Alprazolam | 38 | 14 |
| Atenolol | Atenolol | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 15 |
| Meclizine Hcl | Meclizine Hcl | 25 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 15 |
| Naproxen | Naproxen | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $785.13 · 43 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, EVENITY, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error